{"id":"pioglitazone-tablets","safety":{"commonSideEffects":[{"rate":"5–10","effect":"Weight gain"},{"rate":"5–10","effect":"Fluid retention / edema"},{"rate":"variable","effect":"Hypoglycemia (when combined with other agents)"},{"rate":"5","effect":"Headache"},{"rate":"5","effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a thiazolidinedione, pioglitazone binds to PPAR-γ in adipose tissue and muscle, enhancing insulin signaling and glucose uptake. This reduces hepatic glucose production and improves peripheral insulin sensitivity, leading to lower fasting and postprandial glucose levels. The drug also has favorable effects on lipid metabolism and may reduce cardiovascular risk in certain patient populations.","oneSentence":"Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:31.471Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07289750","phase":"PHASE4","title":"The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-05-01","conditions":"T2DM, MAFLD","enrollment":80},{"nctId":"NCT03499704","phase":"PHASE4","title":"A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2020-02-11","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT07472179","phase":"NA","title":"Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS","status":"COMPLETED","sponsor":"Mst.Sumyara Khatun","startDate":"2024-08-12","conditions":"PCOS(Insulin Resistant)","enrollment":60},{"nctId":"NCT07053319","phase":"PHASE1","title":"SGLT2i, Pioglitazone, and Ketone Production in T2D","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-07-20","conditions":"Type 2 Diabetes","enrollment":64},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT05028140","phase":"PHASE3","title":"Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus","status":"RECRUITING","sponsor":"EMS","startDate":"2024-10-08","conditions":"Type II Diabetes","enrollment":480},{"nctId":"NCT06571591","phase":"PHASE3","title":"Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celltrion","startDate":"2024-08-27","conditions":"T2DM","enrollment":582},{"nctId":"NCT06446531","phase":"PHASE1","title":"Prevention of Progression of Prediabetes, Obesity and CV Risk","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-09-11","conditions":"Pre-Diabetes, Weight, Body, Cardiovascular Diseases","enrollment":64},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT04370093","phase":"PHASE4","title":"Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-10-17","conditions":"Nephrolithiasis, Uric Acid","enrollment":29},{"nctId":"NCT05838287","phase":"PHASE4","title":"Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2023-07-10","conditions":"Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction","enrollment":78},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT06336798","phase":"PHASE2","title":"Bioenergetic Effect of Pioglitazone in CLD-PH","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-12-17","conditions":"Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases","enrollment":20},{"nctId":"NCT06729996","phase":"PHASE2","title":"Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-05-29","conditions":"Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes Mellitus","enrollment":40},{"nctId":"NCT06989723","phase":"PHASE4","title":"Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2025-01-01","conditions":"Type 2 Diabetes, Fatty Liver","enrollment":120},{"nctId":"NCT02852486","phase":"PHASE2","title":"Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2016-06-22","conditions":"Leukemia, Chronic Myeloid","enrollment":31},{"nctId":"NCT05659459","phase":"PHASE2","title":"The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2","status":"TERMINATED","sponsor":"Kinarus AG","startDate":"2022-08-25","conditions":"COVID-19","enrollment":17},{"nctId":"NCT01028963","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-01","conditions":"Type 2 Diabetes Mellitus","enrollment":159},{"nctId":"NCT05582707","phase":"PHASE2","title":"Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2023-05-08","conditions":"Intracerebral Haemorrhage, Intraventricular","enrollment":1},{"nctId":"NCT06594172","phase":"PHASE2","title":"Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2024-09-10","conditions":"Radiation Disease, Cognitive Impairment, Drug Effect","enrollment":67},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT04227093","phase":"PHASE4","title":"Acetazolamide Add-On Therapy to OSA Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2020-01-22","conditions":"Obstructive Sleep Apnea","enrollment":26},{"nctId":"NCT00649012","phase":"PHASE1","title":"Food Study of Pioglitazone HCl Tablets 45 mg to Actos® Tablets 45 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-03","conditions":"Healthy","enrollment":40},{"nctId":"NCT00649558","phase":"PHASE1","title":"Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-02","conditions":"Healthy","enrollment":36},{"nctId":"NCT01135394","phase":"NA","title":"Pharmacogenomics of Thiazolidinediones","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2009-03","conditions":"Type 2 Diabetes","enrollment":114},{"nctId":"NCT06135584","phase":"NA","title":"Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Hangzhou Normal University","startDate":"2023-11-18","conditions":"Metabolic Dysfunction-associated Fatty Liver Disease, Cirrhosis","enrollment":1000},{"nctId":"NCT01990300","phase":"","title":"Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-11-28","conditions":"Type 2 Diabetes Mellitus","enrollment":3281},{"nctId":"NCT04995978","phase":"PHASE2","title":"Insulin Resistance and Androgen Deprivation Therapy","status":"WITHDRAWN","sponsor":"St. Louis University","startDate":"2021-12-01","conditions":"Prostate Cancer, Insulin Resistance","enrollment":""},{"nctId":"NCT05875675","phase":"PHASE2","title":"Effects of Pioglitazone in Calcific Aortic Valve Disease","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-07-01","conditions":"Calcification of Aortic Valve, Aortic Valve Stenosis","enrollment":100},{"nctId":"NCT04658849","phase":"EARLY_PHASE1","title":"Insulin Resistance Following ADT for Prostate CA","status":"WITHDRAWN","sponsor":"St. Louis University","startDate":"2020-12-02","conditions":"Insulin Resistance, Prostate Cancer","enrollment":""},{"nctId":"NCT02917629","phase":"PHASE2","title":"ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-31","conditions":"Oral Cavity Neoplasm, Oropharyngeal Neoplasm, Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7","enrollment":6},{"nctId":"NCT04657939","phase":"PHASE4","title":"Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2020-12-01","conditions":"Diabetes Mellitus, Type 2","enrollment":57},{"nctId":"NCT03060772","phase":"PHASE2","title":"A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)","status":"TERMINATED","sponsor":"Emory University","startDate":"2018-01-03","conditions":"Alcoholism","enrollment":50},{"nctId":"NCT05629806","phase":"PHASE3","title":"Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-04-10","conditions":"Type 2 Diabetes, Blood Glucose Fluctuation","enrollment":50},{"nctId":"NCT05591235","phase":"PHASE3","title":"Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-11","conditions":"Type2diabetes, Insulin Resistance","enrollment":60},{"nctId":"NCT02303405","phase":"PHASE2","title":"Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Charles Drew University of Medicine and Science","startDate":"2014-11","conditions":"Diabetes Mellitus Type 2 With Hyperglycemia","enrollment":22},{"nctId":"NCT05422092","phase":"NA","title":"Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-09-20","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT04123067","phase":"PHASE1, PHASE2","title":"Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2020-09-01","conditions":"Stroke, Acute, Hyperglycemia, Diabetes","enrollment":1},{"nctId":"NCT05521633","phase":"PHASE3","title":"Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2019-06-06","conditions":"NAFLD","enrollment":96},{"nctId":"NCT05519813","phase":"PHASE4","title":"Effects of Pioglitazone Combined With Metformin on Gonadal and Metabolic Profiles in Chinese Nonobese PCOS Patients.","status":"UNKNOWN","sponsor":"Bing He","startDate":"2022-01-01","conditions":"Polycystic Ovary Syndrome","enrollment":60},{"nctId":"NCT05513729","phase":"","title":"Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-08-18","conditions":"Type 2 Diabetes Mellitus With Complication","enrollment":80},{"nctId":"NCT05473806","phase":"PHASE4","title":"Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Seung Up Kim","startDate":"2020-09-18","conditions":"Hepatitis B, Chronic, Fibrosis, Liver, Diabetes Mellitus, Type 2","enrollment":28},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT03011775","phase":"PHASE4","title":"Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease","status":"COMPLETED","sponsor":"Ukrainian Medical Stomatological Academy","startDate":"2012-11","conditions":"Adverse Effect, Atherosclerosis, Coronary, Insulin Resistance Syndrome","enrollment":43},{"nctId":"NCT04980014","phase":"","title":"A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-10-02","conditions":"Type 2 Diabetes Mellitus","enrollment":730},{"nctId":"NCT00484198","phase":"PHASE3","title":"Study of Rivoglitazone in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-04-23","conditions":"Type 2 Diabetes Mellitus","enrollment":1912},{"nctId":"NCT03566225","phase":"EARLY_PHASE1","title":"Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-01-30","conditions":"Pioglitazone","enrollment":400},{"nctId":"NCT00571519","phase":"PHASE3","title":"Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2007-11-14","conditions":"Type 2 Diabetes Mellitus","enrollment":94},{"nctId":"NCT00720577","phase":"EARLY_PHASE1","title":"Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease.","status":"COMPLETED","sponsor":"Medtronic Endovascular","startDate":"2005-12","conditions":"Peripheral Arterial Disease","enrollment":164},{"nctId":"NCT03910361","phase":"PHASE4","title":"Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2019-04-12","conditions":"Type2 Diabetes, Non-Alcoholic Fatty Liver Disease","enrollment":51},{"nctId":"NCT04662866","phase":"PHASE2","title":"Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2021-02-10","conditions":"Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders","enrollment":64},{"nctId":"NCT04604223","phase":"PHASE4","title":"Effect of Pioglitazone on T2DM Patients With COVID-19","status":"UNKNOWN","sponsor":"Dasman Diabetes Institute","startDate":"2021-01-18","conditions":"Covid19, Type 2 Diabetes","enrollment":1506},{"nctId":"NCT03440034","phase":"PHASE1","title":"Study of Pioglitazone in Sporadic Inclusion Body Myositis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-05-22","conditions":"Myositis, Inclusion Body Myositis, Muscular Diseases","enrollment":19},{"nctId":"NCT04671056","phase":"PHASE1","title":"Drug Interaction Study of MGL-3196 With Pioglitazone","status":"COMPLETED","sponsor":"Madrigal Pharmaceuticals, Inc.","startDate":"2018-11-09","conditions":"Healthy","enrollment":16},{"nctId":"NCT00099853","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-05","conditions":"Diabetes Mellitus, Type 2","enrollment":362},{"nctId":"NCT04470310","phase":"PHASE4","title":"Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2015-12-31","conditions":"Type 2 Diabetes Mellitus","enrollment":99},{"nctId":"NCT04584242","phase":"PHASE4","title":"Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2020-09-03","conditions":"Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes","enrollment":40},{"nctId":"NCT03796975","phase":"PHASE4","title":"Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2018-06-28","conditions":"Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Efficacy","enrollment":120},{"nctId":"NCT01068444","phase":"PHASE2","title":"The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2009-04","conditions":"Hepatitis","enrollment":90},{"nctId":"NCT03117517","phase":"EARLY_PHASE1","title":"Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2017-03-20","conditions":"Polycystic Ovarian Syndrome","enrollment":106},{"nctId":"NCT04287387","phase":"PHASE4","title":"Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-03-02","conditions":"Type2 Diabetes Mellitus","enrollment":180},{"nctId":"NCT02689843","phase":"EARLY_PHASE1","title":"Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2018-02-01","conditions":"Polycystic Ovary Syndrome","enrollment":90},{"nctId":"NCT01931566","phase":"PHASE3","title":"Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset","status":"TERMINATED","sponsor":"Takeda","startDate":"2013-08-01","conditions":"Mild Cognitive Impairment Due to Alzheimer's Disease","enrollment":3494},{"nctId":"NCT03864523","phase":"PHASE2","title":"Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy","status":"COMPLETED","sponsor":"Pujol, Aurora, M.D.","startDate":"2016-01","conditions":"Adrenomyeloneuropathy, X-linked Adrenoleukodystrophy","enrollment":18},{"nctId":"NCT03501277","phase":"PHASE1","title":"A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-05-26","conditions":"Healthy Volunteers","enrollment":72},{"nctId":"NCT02284906","phase":"PHASE3","title":"AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease","status":"TERMINATED","sponsor":"Takeda","startDate":"2015-02-12","conditions":"Mild Cognitive Impairment Due to Alzheimer's Disease","enrollment":40},{"nctId":"NCT00094757","phase":"PHASE3","title":"An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-10-06","conditions":"Diabetes Mellitus, Type 2","enrollment":521},{"nctId":"NCT02989649","phase":"","title":"Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice","status":"TERMINATED","sponsor":"Takeda","startDate":"2016-12-22","conditions":"Diabetes Mellitus, Type 2","enrollment":593},{"nctId":"NCT03298464","phase":"PHASE1","title":"Study of NGM313 in Obese Participants","status":"COMPLETED","sponsor":"NGM Biopharmaceuticals, Inc","startDate":"2017-09-11","conditions":"Obese","enrollment":25},{"nctId":"NCT02068508","phase":"","title":"Pioglitazone Tablets Special Drug Use Surveillance \"Combined Use of Insulin Products / Long-term Treatment\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-07-30","conditions":"Type 2 Diabetes Mellitus","enrollment":1067},{"nctId":"NCT02231021","phase":"PHASE4","title":"The Practical Evidence of Antidiabetic Combination Therapy in Korea","status":"COMPLETED","sponsor":"Kun-Ho Yoon","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":216},{"nctId":"NCT02002975","phase":"","title":"Pioglitazone Special Drug Use Surveillance \"Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10-16","conditions":"Type 2 Diabetes Mellitus","enrollment":18223},{"nctId":"NCT02181842","phase":"","title":"Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-01-26","conditions":"Type 2 Diabetes Mellitus","enrollment":246},{"nctId":"NCT00665353","phase":"PHASE2","title":"Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-03","conditions":"HIV-1 and Hepatitis C Co-Infection","enrollment":19},{"nctId":"NCT01972724","phase":"PHASE4","title":"Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-12-16","conditions":"Type II Diabetes Mellitus","enrollment":114},{"nctId":"NCT01217073","phase":"PHASE2","title":"A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":685},{"nctId":"NCT01431521","phase":"PHASE1","title":"Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-26","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":31},{"nctId":"NCT00411892","phase":"PHASE3","title":"Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2006-11-29","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":196},{"nctId":"NCT00770367","phase":"PHASE4","title":"Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2008-10","conditions":"Diabetes","enrollment":36},{"nctId":"NCT03335956","phase":"PHASE1","title":"CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2017-09-21","conditions":"Healthy","enrollment":48},{"nctId":"NCT00212004","phase":"PHASE4","title":"Pioglitazone Protects Diabetes Mellitus (DM) Patients Against Re-Infarction (PPAR Study)","status":"TERMINATED","sponsor":"National Cerebral and Cardiovascular Center, Japan","startDate":"2005-04","conditions":"Diabetes Mellitus, Myocardial Infarction","enrollment":630},{"nctId":"NCT01637935","phase":"","title":"Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-07","conditions":"Diabetes, Bladder Cancer","enrollment":193099},{"nctId":"NCT00782795","phase":"PHASE2","title":"Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2008-11","conditions":"Chronic Pancreatitis, Insulin Resistance, Normal or Mildly Abnormal Stool Fat Levels","enrollment":64},{"nctId":"NCT00855010","phase":"NA","title":"Pioglitazone on Pancreatic Steatosis and Bone Health","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2009-02","conditions":"Obesity, Type 2 Diabetes","enrollment":42},{"nctId":"NCT00500331","phase":"PHASE2","title":"Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-23","conditions":"Diabetes Mellitus, Type 2","enrollment":334},{"nctId":"NCT02371603","phase":"PHASE1","title":"Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-02-11","conditions":"Anaemia","enrollment":70},{"nctId":"NCT01095666","phase":"PHASE3","title":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":1484},{"nctId":"NCT01489943","phase":"PHASE1","title":"A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-09-19","conditions":"Crohn's Disease","enrollment":24},{"nctId":"NCT00634036","phase":"PHASE2","title":"Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics","status":"COMPLETED","sponsor":"Fernando Holguin","startDate":"2009-10","conditions":"Asthma","enrollment":23},{"nctId":"NCT00789750","phase":"PHASE3","title":"Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-04","conditions":"Type 2 Diabetes Mellitus","enrollment":562},{"nctId":"NCT03196362","phase":"PHASE4","title":"Impacts of PIO/MET Following Short-term Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":50},{"nctId":"NCT00532935","phase":"PHASE3","title":"MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-26","conditions":"Type 2 Diabetes Mellitus","enrollment":517},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00722371","phase":"PHASE3","title":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1615},{"nctId":"NCT01028391","phase":"PHASE3","title":"30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00511108","phase":"PHASE1","title":"Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07-11","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":211},{"nctId":"NCT00397631","phase":"PHASE3","title":"Initial Combination With Pioglitazone Study (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-19","conditions":"Type 2 Diabetes Mellitus","enrollment":520},{"nctId":"NCT00086515","phase":"PHASE3","title":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06-30","conditions":"Diabetes Mellitus, Type II","enrollment":701}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pioglitazone Tablets","genericName":"Pioglitazone Tablets","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}